Increased Bone Marrow Activity on F-18-FDG PET/CT in Granulocyte Colony Stimulating Factor Producing Anaplastic Thyroid Carcinoma

2010 ◽  
Vol 35 (2) ◽  
pp. 103-104 ◽  
Author(s):  
Martin Zweifel ◽  
Frank Stenner-Liewen ◽  
Achim Weber ◽  
Panagiotis Samaras ◽  
Kathrin Zaugg ◽  
...  
Author(s):  
Shigeshi Kohno ◽  
Akihiro Furuta ◽  
Shigeki Arizono ◽  
Koji Tokunaga ◽  
Sei Nakao ◽  
...  

AbstractGranulocyte colony-stimulating factor (G-CSF)-producing tumors have an aggressive clinical course. Here, we report five cases of G-CSF-producing tumors and review the literature, focusing on imaging findings related to tumor-produced G-CSF. In addition to our cases, we identified 30 previous reports of G-CSF-producing tumors on which 18F-fluorodeoxyglucose positron emission tomography (FDG-PET)/CT, bone scintigraphy, or evaluation of bone marrow MR findings was performed. White blood cell count, serum C-reactive protein, and serum interleukin-6 were elevated in all cases for which these parameters were measured. G-CSF-producing tumors presented large necrotic masses (mean diameter 83.2 mm, range 17–195 mm) with marked FDG uptake (mean maximum standardized uptake value: 20.09). Diffuse FDG uptake into the bone marrow was shown in 28 of the 31 cases in which FDG-PET/CT was performed. The signal intensity of bone marrow suggested marrow reconversion in all seven MRI-assessable cases. Bone scintigraphy demonstrated no significant uptake, except in two cases with bone metastases. Splenic FDG uptake was increased in 8 of 10 cases in which it was evaluated. These imaging findings may reflect the effects of tumor-produced G-CSF. The presence of G-CSF-producing tumors should be considered in patients with cancer who show these imaging findings and marked inflammatory features of unknown origin.


2008 ◽  
Vol 22 (7) ◽  
pp. 635-639 ◽  
Author(s):  
Miyako Morooka ◽  
Kazuo Kubota ◽  
Yuji Murata ◽  
Hitoshi Shibuya ◽  
Kimiteru Ito ◽  
...  

2013 ◽  
Vol 48 (1) ◽  
pp. 63 ◽  
Author(s):  
Keunhee Kang ◽  
Joo Hee Park ◽  
Ja Young Ryu ◽  
Sang Yup Lee ◽  
Gang Jee Ko ◽  
...  

Surgery Today ◽  
2005 ◽  
Vol 36 (1) ◽  
pp. 63-67 ◽  
Author(s):  
Takeo Fujita ◽  
Yutaka Ogasawara ◽  
Minoru Naito ◽  
Hiroyoshi Doihara ◽  
Nobuyoshi Shimizu

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Kazuna Kawabata ◽  
Makoto Hosono ◽  
Hiroki Tanaka ◽  
Mizuki Hyuga ◽  
Mitsunori Kanagaki

Medicine ◽  
2017 ◽  
Vol 96 (6) ◽  
pp. e5621
Author(s):  
Elisa Giannetta ◽  
Andrea M. Isidori ◽  
Cosimo Durante ◽  
Cira Di Gioia ◽  
Flavia Longo ◽  
...  

Surgery Today ◽  
1995 ◽  
Vol 25 (2) ◽  
pp. 158-160 ◽  
Author(s):  
Kazunori Iwasa ◽  
Masakuni Noguchi ◽  
Kazuhiro Mori ◽  
Nagayoshi Ohta ◽  
Itsuo Miyazaki ◽  
...  

2020 ◽  
Author(s):  
F Ahmaddy ◽  
V Wenter ◽  
L Beyer ◽  
H Ilhan ◽  
S Lehner ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
May Sadik ◽  
Jesús López-Urdaneta ◽  
Johannes Ulén ◽  
Olof Enqvist ◽  
Armin Krupic ◽  
...  

AbstractTo develop an artificial intelligence (AI)-based method for the detection of focal skeleton/bone marrow uptake (BMU) in patients with Hodgkin’s lymphoma (HL) undergoing staging with FDG-PET/CT. The results of the AI in a separate test group were compared to the interpretations of independent physicians. The skeleton and bone marrow were segmented using a convolutional neural network. The training of AI was based on 153 un-treated patients. Bone uptake significantly higher than the mean BMU was marked as abnormal, and an index, based on the total squared abnormal uptake, was computed to identify the focal uptake. Patients with an index above a predefined threshold were interpreted as having focal uptake. As the test group, 48 un-treated patients who had undergone a staging FDG-PET/CT between 2017–2018 with biopsy-proven HL were retrospectively included. Ten physicians classified the 48 cases regarding focal skeleton/BMU. The majority of the physicians agreed with the AI in 39/48 cases (81%) regarding focal skeleton/bone marrow involvement. Inter-observer agreement between the physicians was moderate, Kappa 0.51 (range 0.25–0.80). An AI-based method can be developed to highlight suspicious focal skeleton/BMU in HL patients staged with FDG-PET/CT. Inter-observer agreement regarding focal BMU is moderate among nuclear medicine physicians.


Sign in / Sign up

Export Citation Format

Share Document